HilleVax, Inc. (HLVX)
| Market Cap | 606.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -175.95M |
| Shares Out | 33.35M |
| EPS (ttm) | -27.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,587 |
| Open | 16.91 |
| Previous Close | 17.27 |
| Day's Range | 16.91 - 18.26 |
| 52-Week Range | 7.90 - 24.42 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 35.36 (+95.68%) |
| Earnings Date | n/a |
About HLVX
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for HLVX stock is "Buy." The 12-month stock price forecast is $35.36, which is an increase of 95.68% from the latest price.
News
HilleVax Announces Executive Management Appointments and Promotions
BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appoin...
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it wi...
After Plunging 32.4% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax, Inc. (HLVX)
HilleVax, Inc. (HLVX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings esti...
Down 25.2% in 4 Weeks, Here's Why You Should You Buy the Dip in HilleVax, Inc. (HLVX)
HilleVax, Inc. (HLVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in rev...
HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported results fro...
Here's Why "Trend" Investors Would Love Betting on HilleVax, Inc. (HLVX)
HilleVax, Inc. (HLVX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it throu...
Wall Street Analysts Predict a 67% Upside in HilleVax, Inc. (HLVX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 67% in HilleVax, Inc. (HLVX). While the effectiveness of this highly sought-after metric is questionable, the p...
HilleVax to Participate in November Investor Conferences
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it wi...
HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it w...
HilleVax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum
BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it wi...
HilleVax Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
BOSTON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial r...
HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate
Pan-Ig and HBGA blocking antibody responses persisted to year 5
Biotech Public Offerings at 10-Year Low
No matter how you slice it, this has been a poor year for biotechnology stocks. Not only is the SPDR S&P Biotech ETF ( XBI , Financial) down nearly 29% year to date, but biotech initial public offerin...
HilleVax Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
Initiated Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants (NOR-212)